SHIELD THERAPEUTICS PLC - Full year trading update

(42:53)

Shield Therapeutics to take on US market solo and hopes to reap the benefits

(8:34)

Shield Therapeutics at the Hardman \u0026 Co Investor Forum | November 2024

(23:20)

Shield Therapeutics Eyes Cash Flow Positive Target by 2025

(7:9)

Shield Therapeutics wraps up strong first half as Accrufer gains more traction in the US

(10:59)

SHIELD THERAPEUTICS PLC - Q3 Trading Update

(39:18)

Bitesize briefing – Shield Therapeutics

(5:17)

Shield Therapeutics \

(7:22)

Shield Therapeutics talks extension of cash runway following US$10 million financing

(9:22)

Why your CORRECTIONS don’t work on your Dog!

(21:32)

The Exchange with Gervais Williams of Premier Miton

(58:30)

Blue Cross Blue Shield Antitrust Settlement for $2.7 Billion

(4:34)

Investor Forum | Full recording: STX, WNWD, CREI, EDX and Mike Foster presentations

(1:42:28)

Amplia Therapeutics (ASX:ATX) | Webinar with Chris Burns | 11/06/24

(32:16)

The Science Behind Pancreatic Cancer Therapeutics

(33:38)

ASX Daily Rundown | Telstra Suprises, Megaport and Nanosonics SOAR, Banks Tumble Again

(50:9)

Sernova’s Cell Pouch System tackles diabetes

(11:4)

Scancell Holdings \

(6:32)

SHIELD THERAPEUTICS PLC - Business Update for Q1 2024 and Confirmation of Key Financials for FY 202

(59:39)

Shield Therapeutics March 2020 Investor Forum Presentation

(30:42)

SHIELD THERAPEUTICS PLC - Interim results

(45:53)

Shield Therapeutics 'making very good commercial progress' says Proactive Research

(3:55)

Shield Therapeutics' Feraccru drug 'a potential game-changer' - Capital Network Analyst

(4:)

Shield Therapeutics CEO hails positive head-to-head Feraccru study results

(5:29)

Life Sciences Investor Forum | Shield Therapeutics

(29:5)

Shield Therapeutics: building the brand base as it progresses with Accrufer launch process

(5:44)

LSX World Congress 2019 Presentations - Shield Therapeutics

(16:43)

2236: Shield Therapeutics and Russ Mould on U.S. Stimulus and Markets Looking Forward

(36:1econd)

Shield Therapeutics CEO says reanalysis of key study has shown Feraccru to be 'credible alternative'

(8:53)